The impact of sedative and vasopressor agents on cerebrovascular reactivity in severe traumatic brain injury

Intensive Care Medicine Experimental

Table 2 Continuous infusion response

Name	Doses	Mean dose change	% time LPRx_10 > 0
Name	Doses	Mean dose change	Pre-dose	Post-dose	p value	Adj p value
Dobutamine	1519	Decrease	50 (30–68.4)	51.1 (33.3–68.2)	0.295	1
Dobutamine	1222	Increase	50 (30.8–68.1)	50 (30.8–69.2)	0.462	1
Midazolam	5383	Decrease	50 (31.2–67.9)	50 (31.6–67.6)	0.569	1
Midazolam	5178	Increase	50 (31.2–69)	50 (31.8–67.7)	0.131	1
Morphine	8189	Decrease	50.5 (32.1–68)	50 (33.3–67.9)	0.889	1
Morphine	7931	Increase	50 (31–69.2)	50 (32.1–67.9)	0.362	1
Noradrenaline	53,311	Decrease	50 (32–68)	50 (31–67.9)	0.297	1
Noradrenaline	49,928	Increase	50 (31–68)	50 (31–67.9)	0.00673	0.182
Propofol	16,559	Decrease	50 (32–68)	50 (32.6–68.2)	0.375	1
Propofol	14,898	Increase	50 (32–69)	50 (32–67.9)	0.27	1
Vasopressin	78	Decrease	53.7 (51.7–58.1)	53.3 (51.2–54.7)	0.132	1
Vasopressin	66	Increase	53.5 (42–58.9)	52 (45.3–54.2)	0.372	1

The table demonstrates the median and interquartile range of the pre/pose dose windows as well as the Wilcoxon signed-ranked test between these windows with a p value adjust using the Bonferroni analysis. The “change” indicates if the continuous infusion was increase/decrease dose. Note that although noradrenaline showed significance, given that the median value pre–post dose is 0 there is limited evidence that this is a true significant change. LPRx_10, pressure reactivity over 10 min